JSR Life Sciences’ parent corp. will pay NT$12 billion ($400 million) for Crown Bioscience International, boosting its global footprint and CRO offerings.
Crown Bioscience has offices across the U.S., Europe, China and Taiwan and works with a portfolio of translational platforms for oncology and CVMD. It touts itself as showing insight into a drug’s efficacy, pharmacological profile and patient response profile, which it says helps toward “reducing failure in the clinic, and supporting the selection of the right patients for the right therapy.”
The deal marks JSR’s largest life sciences-focused investment to date, boosting its portfolio with a CRO and its worldwide locations.
“We are positioning to be the clear choice for innovation-driven strategic partnerships,” said Eric Johnson, president of JSR’s life sciences division. “CrownBio, and its science-rich approach, is an ideal fit to support that goal. We’re bringing together innovative competencies that will lead to better solutions for pharma and improve their ability to take therapeutics to the market.”
JSR Life Sciences’ division, with bases in Tokyo, Sunnyvale, Leuven and Beijing, predominately works on materials for biopharma manufacturing processes, as well as for life science research applications, in vitro diagnostics and medical devices.
JSR says it forecast, based “on consultation” with CrownBio’s management team, sees sales and EBITDA margins of “$90 million and $20 million, respectively in 2018.”
This comes amid an M&A spurt from the company, which in the last few years has bought out CDMO KBI Biopharma and MBL Corporation, as well as Selexis earlier this year.
“JSR envisions that CrownBio’s development capabilities will enhance the contribution of JKiC, the company’s Japan-based industry-academia-medicine collaboration hub, by providing the tools and expertise to translate leading-edge research into tomorrow’s medicines,” the company said in a statement.
By Ben Adams
Source: Fierce Biotech
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
